Table 3.

Overview of the COVID-19 vaccine research landscape and evidence from Africa: post marketing effectiveness studies^a

Country	Title	Trial No	Vaccine	Sample size/age	Outcome
Egypt	Impact of COVID 19 Vaccine on Safety, Blood Elements, and Immunogenicity of the Egyptian Population	NCT04809948	ChAdOx1 nCoV-19 /AstraZeneca	800, 18-80 years	adverse side effects, hematological values; immunogenicity
Egypt	T Cell, Antibody and Cytokine Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians	NCT04706143	Lived attenuated (Sinopharm), mRNA (Pfizer/ BioNtech) and viral vector (Oxford/AastarZeneca) vaccines	100, 25-65 years	T Cell, Antibody and Cytokine Responses
South Africa	Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (SISONKE study)	NCT04838795	Ad26.COV2.S/Johnson & Johnson	500,000, ≥ 18 years	effectiveness on severe COVID, hospitalizations and deaths in HCWs

^aReferenced from WHO Landscape of observational study designs on the effectiveness of COVID-19 vaccination (version 19^th April 2021)